SN1
SHORT NOTE
5M
★ High-yield
Describe the multiple endocrine neoplasia syndromes.
Definition and Classification
Multiple endocrine neoplasia (men) syndromes are autosomal dominant disorders in which tumours or hyperplasia arise in several endocrine organs in the same patient.
| Syndrome | Gene | Components |
|---|---|---|
| Men 1 (Wermer) | MEN1 on chromosome 11 — a tumour suppressor (menin) | The "3 Ps" — parathyroid hyperplasia (the commonest and usually first), pancreatic endocrine tumours (gastrinoma causing zollinger–ellison syndrome, insulinoma), and pituitary adenoma (most often prolactinoma) |
| Men 2A (Sipple) | RET on chromosome 10 — a proto-oncogene | Medullary thyroid carcinoma (over 95%), phaeochromocytoma (about 50%), and parathyroid hyperplasia |
| Men 2B | RET (codon 918) | Medullary thyroid carcinoma and phaeochromocytoma, but NO parathyroid disease; plus mucosal neuromas, intestinal ganglioneuromatosis and a marfanoid habitus |
CLINICAL PEARL
Men 1 is caused by a tumour suppressor and men 2 by an oncogene, and that difference is clinically useful. A tumour suppressor needs two hits, so men 1 tumours arise sporadically over time and cannot be pre-empted. An activating oncogene mutation is present and active in every cell, so medullary carcinoma is near-inevitable in men 2 — which is why prophylactic thyroidectomy in childhood is offered to RET carriers and has no equivalent in men 1.
Clinical Presentation
- Men 1 most often presents with hypercalcaemia from parathyroid hyperplasia — often asymptomatic and found on biochemistry
- Gastrinoma in men 1 causes multiple, recurrent peptic ulcers in unusual sites with diarrhoea, resistant to standard treatment
- Men 2 presents with medullary thyroid carcinoma or with the catecholamine symptoms of phaeochromocytoma
- Men 2B has the worst prognosis, with medullary carcinoma appearing in infancy; the mucosal neuromas and marfanoid habitus may be recognised before any endocrine problem
Applied Aspects
- Always exclude phaeochromocytoma before any surgery in a patient with men 2 — operating on an undiagnosed phaeochromocytoma can precipitate a fatal hypertensive crisis
- Genetic testing of first-degree relatives is mandatory once a proband is identified; RET testing is straightforward and highly informative
- Prophylactic total thyroidectomy is offered to RET mutation carriers, with the timing determined by the specific codon — in infancy for men 2B
- Serum calcitonin is used for diagnosis and for surveillance of medullary carcinoma
- Consider men in anyone with two endocrine tumours, or with a single endocrine tumour at an unusually young age or with a family history — the diagnosis changes management for the whole family, not just the patient
- Parathyroid disease in men 1 is usually multigland hyperplasia, not a single adenoma, so subtotal or total parathyroidectomy with autotransplantation is required — removing one gland fails
- Lifelong surveillance is needed, since new tumours continue to arise; biochemical screening is repeated annually with periodic imaging
- Other familial endocrine syndromes — von Hippel–Lindau (phaeochromocytoma, renal cell carcinoma, haemangioblastoma), neurofibromatosis 1, and Carney complex; the presence of a phaeochromocytoma should always prompt genetic assessment
- Genetic counselling before testing is essential, since a positive result has implications for insurance, employment and family relationships as well as for health
- Management should be by a multidisciplinary team — endocrinologist, surgeon, geneticist and pathologist — because no single specialty sees the whole syndrome
- The pancreatic tumours of men 1 determine survival, since they are often multiple, malignant and difficult to localise — unlike the parathyroid disease, which is readily treated
- Recurrent peptic ulceration with hypercalcaemia is a classical clue to men 1, and should not be treated as two unrelated problems
- Men syndromes are rare, but recognising one transforms outcomes for relatives who can be screened and treated before disease develops
All questions in Endocrine, Bone & Breast Pathology
- Q1Classify diabetes mellitus. Differentiate type 1 from type 2 and describe the pathogenesis, morphology of complications and acute metabolic emergencies. ★
- Q2Classify thyroid disorders. Describe Graves disease, Hashimoto thyroiditis and the carcinomas of the thyroid. ★
- Q3Describe Cushing syndrome with its causes and investigation. Add notes on adrenal insufficiency, phaeochromocytoma and pituitary disorders. ★
- Q4Classify breast lesions. Describe the risk factors, classification, morphology and prognostic factors of breast carcinoma. ★
- Q5Describe the metabolic bone diseases. Add notes on osteomyelitis and the classification and features of bone tumours. ★
- SN1Describe the multiple endocrine neoplasia syndromes. ★
- SN2Define osteoporosis. Describe its causes, pathogenesis and diagnosis. ★
- SN3Describe fibroadenoma of the breast and differentiate it from a phyllodes tumour. ★
- SN4Define goitre. Describe the causes and pathogenesis of simple and multinodular goitre. ★
- SN5Describe carcinoma of the cervix with its aetiology, precursor lesions and prevention. ★
- SN6Describe gestational trophoblastic disease. Differentiate complete from partial mole and add a note on choriocarcinoma.
- SN7Describe hypothyroidism and hyperthyroidism with their causes, features and the interpretation of thyroid function tests. ★